Function and mechanism by which interferon regulatory factor-1 inhibits oncogenesis (Review)

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 417-423

  Chen, Fei Fei ^a   Jiang, Guan ^a   Xu, Kerui ^b   Zheng, Jun Nian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b WAKE FOREST UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle; Immune response; IRF 1; Oncogenesis

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN 2 RECEPTOR; BETA INTERFERON; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CASPASE 7; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOKINE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN P53; PUMA PROTEIN; STAT1 PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CYCLE REGULATION; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MYELODYSPLASTIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84871537012     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1051     Document Type: Review

References (79)

1. Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R and Hiscott J: Interferon regulatory factors: the next generation. Gene 237: 1-14, 1999.
2. Taniguchi T, Ogasawara K, Takaoka A and Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19: 623-655, 2001.
3. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM and Maniatis T: Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell 1: 507-518, 1998.
4. Meraro D, Hashmueli S, Koren B, Azriel A, Oumard A, Kirchhoff S, Hauser H, Nagulapalli S, Atchison ML and LeviBZ: Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J Immunol 163: 6468-6478, 1999.
5. Lohoff M and Mak TW: Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 5: 125-135, 2005.
6. Nobuyuki T and Tadatsugu T: The interferon regulatory factors and oncogenesis. Semin Cancer Biol 10: 73-81, 2000.
7. Fujita T, Sakakibara J, Sudo Y, Miyamoto M, Kimura Y and Taniguchi T: Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO J 7: 3397-3405, 1988.
8. Mamane Y, Grandvaux N, Hernandez E, Sharma S and InnocenteSA: Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene 21: 6751-6765, 2002.
9. Xu DS, Zhao LJ, Valle LD, Miklossy J and Zhang LW: Interferon regulatory factor 4 is involved in Epstein-Barr Virus-mediated transformation of human B lymphocytes. J Virol 82: 6251-6258. 2008.
10. Xu D, Meyer F, Ehlers E, Blasnitz L and Zhang L: Interferon regulatory factor 4 (IRF-4) targets IRF-5 to regulate Epstein-Barr virus transformation. J Biol Chem 286: 18261-18267, 2011.
11. Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA and Pitha PM: Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res 63: 6424-6431, 2003.
12. Deng M and Daley GQ: Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood 97: 3491-3497, 2001.
13. Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan NV, SeftorRE, Wheaton WW, Amir S, Pins MR, Schutte BC and Hendrix MJ: Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem 280: 34210-34217, 2005.
14. Zhao Y, Xu DS, Jiang YJ and Zhang LW: Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes. PLoS One 5: e9459, 2010.
15. Itoh S, Harada H, Nakamura Y, White R and Taniguchi T: Assignment of the human interferon regulatory factor-1 (IRF1) gene to chromosome 5q23-q31. Genomics 10: 1097-1099, 1991.
16. Willman CL, Sever CE, Pallavicini MG, Harada H, TanakaN, Slovak ML, Yamamoto H, Harada K, Meeker TC and List AF: Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259: 968-971, 1993.
17. Ogasawara S, Tamura G, Maesawa C, Suzuki Y, Ishida K, SatohN, Uesugi N, Saito K and Satodate R: Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology 110: 52-57, 1996.
18. Tamura G, Ogasawara S, Nishizuka S, Sakata K, Maesawa C, Suzuki Y, Terashima M, Saito K and Satodate R: Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res 56: 612-615, 1996.
19. Nozawa H, Oda E, Ueda S, Tamura G, Maesawa C, Muto T, Taniguchi T and Tanaka N: Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int J Cancer 77: 522-527, 1998.
20. Cavalli LR, Riggins RB, Wang A, Clarke R and Haddad BR: Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat 121: 227-231, 2010.
21. Bouker KB, Skaar TC, Harburger DS, Riggins RB, FernandezDR, Zwart A and Clarke R: The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. Cancer Genet Cytogenet 175: 61-64, 2007.
22. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, PasqualucciL, Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, PaciniR, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG and Martelli MF: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352: 254-266, 2005.
23. Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T and Tanaka N: Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene 15: 1275-1281, 1997.
24. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, TanakaN, Lamphier MS, Hirai H and Taniguchi T: Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 9: 3313-3320, 1994.
25. Tzoanopoulos D, Speletas M, Arvanitidis K, Veiopoulou C, Kyriaki S, Thyphronitis G, Sideras P, Kartalis G and Ritis K: Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br J Haematol 119: 46-53, 2002.
26. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE and Um SJ: Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275: 6764-6769, 2000.
27. Junsoo P, Kim K, Lee EJ, Seo YJ, Lim SN, Park K, Rho SB, LeeSH and Lee JH: Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc Natl Acad Sci USA 104: 17028-17033, 2007.
28. Tamura T, Yanai H, Savitsky D and Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26: 535-584, 2008.
29. Takaoka A, Tamura T and Taniguchi T: Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci 99: 467-478, 2008.
30. Tanaka N, Ishihara M, Kitagawa M, Harada H, KimuraT, Matsuyama T, Lamphier MS, Aizawa S, Mak TW and TaniguchiT: Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77: 829-839, 1994.
31. Passioura T, Dolnikov A, Shen S and Symonds G: N-ras induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res 65: 797-804, 2005.
32. Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, Ogasawara K, Nakatsuru Y, Shimizu S, Ohira Y, Hioki K, AizawaS, Ishikawa T, Katsuki M, Muto T, Taniguchi T and Tanaka N: Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev 13: 1240-1245, 1999.
33. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S and Affabris E: IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 22: 39-47, 2002.
34. Benech P, Vigneron M, Peretz D, Revel M and Chebath J: Interferon-responsive regulatory elements in the promoter of the human 2',5'-oligo(A)synthetase gene. Mol Cell Biol 7: 4498-4504, 1987.
35. Takikawa O, Kuroiwa T, Yamazaki F and Kido R: Mechanism of interferon-γ action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-γ and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263: 2041-2048, 1988.
36. Kirchhoff S, Koromilas AE, Schaper F, Grashoff M, Sonenberg N and Hauser H: IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR. Oncogene 11: 439-445, 1995.
37. Pamment J, Ramsay E, Kelleher M, Dornan D and Ball KL: Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene 21: 7776-7785, 2002.
38. Tan RS, Taniguchi T and Harada H: Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1 and its possible role in tumor suppression. Cancer Res 56: 2417-2421, 1996.
39. Horiuchi M, Yamada T, Hayashida W and Dzau VJ: Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. J Biol Chem 272: 1952-1958, 1997.
40. Clarke N, Jimenez AM, Voltz E and Gronemeyer H: Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J 23: 3051-3060, 2004.
41. Chin YE, Kitagawa M, Kuida K, Flavell RA and Fu XY: Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 17: 5328-5337, 1997.
42. Sancéau J, Hiscott J, Delattre O and Wietzerbin J: IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19: 3372-3383, 2000.
43. Ruiz C, Ruiz AC, Rodriguez A, Ortiz G, Redondo JM and LópezA: The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem 279: 19712-19720, 2004.
44. Jeay S, Pianetti S, Kagan HM and Sonenshein GE: Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-κB. Mol Cell Biol 23: 2251-2263, 2003.
45. Kroger A, Dallugge A, Kirchhoff S and Hauser H: IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Oncogene 22: 1045-1056, 2003.
46. Kroger A, Stirnweiss A, Pulverer JE, Klages, Grashoff M, Reimann J and Hauser H: Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclinD1. Cancer Res 67: 2972-2981, 2007.
47. Pizzoferrato E, Liu Y, Gambotto A, Armstrong MJ, Stang MT, Gooding WE, Alber SM, Shand SH, Watkins SC and Storkus WJ: Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res 64: 8381-8388, 2004.
48. Frontini M, Vijayakumar M, Garvin A and Clarke N: A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response. Nucleic Acids Res 37: 1073-1085, 2009.
49. Walsh T and King MC: Ten genes for inherited breast cancer. Cancer Cell 11: 103-105, 2007.
50. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, BarfootR, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK); Easton DF, Stratton MR and Rahman N: Truncating mutations in the Fanconi anemia J gene BRIP1 are low penetrance breast cancer susceptibility alleles. Nat Genet 38: 1239-1241, 2006.
51. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M and Taniguchi T: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and-2. Science 259: 971-974, 1993.
52. Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS and van Wijnen AJ: The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 278: 26589-26596, 2003.
53. Mori K, Yoshida K, Tani J, Nakagawa Y, Hoshikawa S and ItoS: Double-stranded RNA-induced interferon regulatory factor-1 gene expression in FRTL-5 rat thyroid cells. Mol Cell Endocrinol 84: 77-86, 2001.
54. Wang J, Zhang WJ, Zhang YS, Chen Y, Zou B, Jiang B, Pang R, Gu Q, Qiao L, Lan HY, Kung HF and Wong BC: c-Jun N-terminal kinase (JNK1) upregulates XIAP-associated factor 1 (XAF1) through interferon regulatory factor 1 (IRF-1) in gastrointestinal cancer. Carcinogenesis 30: 222-229, 2009.
55. Nguyen H, Lin R and Hiscott J: Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene 15: 1425-1435, 1997.
56. Savitsky D, Tamura T, Yanai H and Taniguchi T: Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 59: 489-510, 2010.
57. Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79: 329-339, 1994.
58. Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S and Taniguchi T: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376: 596-599, 1995.
59. Bowie ML, Ibarra C and Seewalt VL: IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis. Adv Exp Med Biol 617: 367-374, 2008.
60. Gao J, Senthil M, Ren B, Yan J, Xing Q, Yu J, Zhang L and YimJH: IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cells. Cell Death Differ 17: 699-709, 2009.
61. Lallemand C, Palmieri M, Blanchard B, Meritet JF and ToveyMG: GAAP-1: a transcriptional activator of p53 and IRF-1 possesses proapoptotic activity. EMBO Rep 3: 153-158, 2002.
62. Kim EJ, Lee JM, Namkoong SE, Um SJ and Park JS: Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 85: 369-380, 2002.
63. Fulda S and Debatin KM: IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21: 2295-2308, 2002.
64. Bouker KB, Skaar TC, Riggins R, Harburger DS, Fernandez DR, Zwart A, Wang A and Clarke R: Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis 26: 1527-1535, 2005.
65. De Ambrosis A, Casciano I, Croce M, Pagnan G, Radic L, Banelli B, Di Vinci A, Allemanni G, Tonini GP, Ponzoni M, Romani M and Ferrini S: An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. Int J Cancer 120: 39-47, 2007.
66. Tomita Y, Bilim V, Hara N, Kasahara T and Takahashi K: Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer 104: 400-408, 2003.
67. Park SY, Seol JW, Lee YJ, Cho JH, Kang HS and Kim IS: IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem 271: 4222-4228, 2004.
68. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, ShinoharaM, Takayanagi H, Ohba Y, Taniguchi T and Honda K: Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in toll-like receptor dependent gene induction program. Proc Natl Acad Sci USA 103: 15136-15141, 2006.
69. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, Hida S, SuzukiG, Mitsuyama M, Shin EH, Kojima S, Taniguchi T and AsanoY: Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6: 673-679, 1997.
70. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
71. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi T, Waldmann TA, Taniguchi T and Taki S: Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391: 700-703, 1998.
72. Gabriele L, Fragale A, Borghi P, Sestili P, Stellacci E, VendittiM, Schiavoni G, Sanchez M, Belardelli F and Battistini A: IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol 80: 1500-1511, 2006.
73. Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, KawakamiT, Watanabe N, Kundig TM, Amakawa R, Kishihara K and Wakeham A: Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell 75: 83-97, 1993.
74. Reis LF, Ruffner H, Stark G, Aguet M and Weissmann C: Mice devoid of interferon regulatory factor 1 (IRF-1) show normal expression of type I interferon genes. EMBO J 13: 4798-4806, 1994.
75. White LC, Wright KL, Felix NJ, Ruffner H, Reis LF, Pine R and Ting JP: Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8 + T cells in IRF-1-/-mice. Immunity 5: 365-376, 1996.
76. Penninger JM, Sirard C, Mittrucker HW, Chidgey A, KozieradzkiI, Nghiem M, Hakem A, Kimura T, Timms E, BoydR, Taniguchi T, Matsuyama T and Mak TW: The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity 7: 243-254, 1997.
77. Lohoff M, Ferrick D, Mittrucker HW, Duncan GS, Bischof S, Rollinghoff M and Mak TW: Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity 6: 681-689, 1997.
78. Wiwanitkit V: Interaction between interferon regulatory factor-1 and human papillomavirus E7 oncogene in cervical cancer: an ontology study. Taiwan J Obstet Gynecol 48: 138-141, 2009.
79. MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350, 1997.